BofA update shows where active managers are putting money
HENDERSON, NV—Daniel R. Henry, a director at Paysign, Inc. (NASDAQ:PAYS), has recently acquired a significant amount of the company’s common stock. According to a filing with the Securities and Exchange Commission, Henry purchased 10,084 shares on June 16, 2025. The shares were bought at a weighted average price of $4.9583, with the transaction totaling approximately $50,000. The purchase comes as Paysign shares have shown remarkable strength, with a 65% gain over the past six months and the stock currently trading at $5.12.
The acquisition boosts Henry’s direct ownership in Paysign to 129,884 shares. The purchase was executed through multiple transactions at prices ranging from $4.9385 to $4.99 per share. According to InvestingPro data, the company, currently valued at $278 million, is trading near its Fair Value, with analysts projecting profit growth this year. This move signals Henry’s continued confidence in the company’s prospects and aligns with his role as a director.[Get access to 10+ additional ProTips and comprehensive analysis for Paysign and 1,400+ stocks with InvestingPro]
In other recent news, Paysign Inc. reported impressive first-quarter earnings for 2025, with a significant 41% increase in total revenue, reaching $18.6 million. The company’s earnings per share (EPS) of $0.05 far exceeded the forecast of $0.01, showcasing a robust financial performance. DA Davidson responded to these results by raising its price target for Paysign to $6.00, maintaining a Buy rating, and highlighting the company’s strong quarterly report. Additionally, Paysign announced an expansion in its plasma donation center network, adding 132 centers, which will increase its total to 615 centers and boost its U.S. market share to approximately 50%.
This expansion is expected to drive immediate revenue growth without increasing Selling, General and Administrative (SG&A) expenses, demonstrating the company’s operating leverage. DA Davidson further raised its price target to $8.00, citing Paysign’s expansion in the plasma industry as a key factor for raising financial forecasts for 2025 and 2026. During its annual stockholders meeting, Paysign elected all seven nominees to the Board of Directors and approved executive compensation measures. The company also ratified Moss Adams LLP as its independent auditor for the fiscal year 2025. These developments reflect Paysign’s strategic efforts to enhance its market position and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.